Effect of tranilast in early-stage diabetic nephropathy

Nephrology Dialysis Transplantation

Volumn 21, Issue 10, 2006, Pages 2795-2799

  Soma, Jun ^a   Sato, Kozo ^a   Saito, Harutaka ^a   Tsuchiya, Yoshinori ^a  

^a Iwate Prefectural Central Hospital   (Japan)

Author keywords

Albuminuria; Collagen; Diabetic nephropathy; Extracellular matrix; Tranilast

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; COLLAGEN TYPE 4; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; INSULIN; TRANILAST;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MALE; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; URINARY EXCRETION;

AGED; ALBUMINURIA; ANALYSIS OF VARIANCE; ANTHRANILIC ACIDS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; COLLAGEN TYPE IV; CREATININE; DIABETIC NEPHROPATHIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; TREATMENT OUTCOME;

EID: 33749618332     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl325     Document Type: Article

References (44)

1. D'Amiko G. Renal replacement therapy throughout the world: The registries. Am J Kidney Dis 1995; 25: 113-118
2. Teraoka S, Toma H, Nihei H et al. Current status of renal replacement therapy in Japan. Am J Kidney Dis 1995; 25: 151-164
3. The Kroc Collaborative Study Group. Diabetic nephropathy after two years of intensified insulin treatment. Follow-up of the Kroc Collaborate Study. JAMA 1988; 260: 37-41
4. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br J Med 1982; 285: 685-688
5. Nelson RG, Pettitt DJ, Carrher MJ, Baird HR, Knowler WC. Effect of proteinuria on mortality in NIDDM. Diabetes 1988; 37: 1499-1504
6. Mulec H, Johnson SA, Björck S. Relation between serum cholesterol and diabetic nephropathy. Lancet 1990; 335: 1537-1538
7. Friedman EA. Race and diabetic nephropathy. Transplant Proc 1987; 19 [Suppl 2]: 77-81
8. Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease: Evidence of genetic susceptibility to diabetic nephropathy. N Engl J Med 1989; 320: 1161-1165
9. Barnes DJ, Pinto JR, Viberti G. The patients with diabetes mellitus. In: Davison AM, Cameron JS, Grunfeld JP, Kerr DNS, Ritz E, Winearls CG, eds. Oxford Text Book of Clinical Nephrology. Oxford University Press, 1998; 746-775
10. Nerlich A, Schleicher E. Immunohistological localization of extracellular matrix components in human diabetic glomerular lesions. Am J Pathol 1991; 139: 889-899
11. Esposito C, Patel A, Lin ZH, Striker GE, Striker LJ. Involvement of synthesis and degradation pathways of collagen type IV in human glomerulosclerosis: Molecular analysis by in situ reverse transcription and competitive polymerase chain reaction. Contrib Nephrol 1996; 118: 12-16
12. Suzawa H, Kikuchi S, Ichikawa K, Koda A. Inhibitory action of tranilast, anti-allergic drug, on the release of cytokines and PGE2 from human monocytes-macrophages. Jpn J Pharmacol 1992; 60: 85-90
13. Yamada H, Tajima S, Nishikawa T, Murad S, Pinnell SR. Tranilast, a selective inhibitor of collagen synthesis in human skin fibroblasts. J Biochem 1994; 116: 892-897
14. Soma J, Sugawara, T, Huang Y-D, Nakajima N, Kawamura M. Tranilast slows the progression of advanced diabetic nephropathy. Nephron 2002; 92: 693-698
15. Ishii S, Wada M, Yanada T, Iimura, Y, Itoh Y, Sakurabayashi I. Latex turbidimetric immunoassay with LA-system for urinary for albumin. Jpn J Clin Lab Aut 1987; 12: 78-82 (in Japanese)
16. Iijima T, Suzuki S, Sekizuka K et al. Follow-up study on urinary type IV collagen in patients with early stage diabetic nephropathy. J Clin Lab Anal 1998; 12: 378-382
17. Taniguchi S, Yorifumi T, Hamada T. Treatment of linear localized scleroderma with the anti-allergic drug, tranilast. Clin Exp Dermatol 1994; 19: 391-393
18. Umemura K, Kikuchi S, Suzuki Y, Nakashita M. Inhibitory effect of tranilast on hypertrophic collagen production in the spontaneously hypertensive rat heart. Jpn J Pharmacol 1998; 78: 161-167
19. Fukuyama J, Miyazaki K, Hamano S, Ujiie A. Inhibitory effects of tranilast on proliferation, migration, and collagen synthesis of human vascular muscle cells. Can J Pharmacol 1996; 74: 80-84
20. Tanaka K, Honda M, Kuramochi T, Morioka S. Prominent inhibitory effects of tranilast on migration and proliferation of and collagen synthesis by vascular smooth muscle cells. Atherosclerosis 1994; 107: 179-185
21. Miyazawa K, Kikuchi S, Fukuyama J, Hamano S, Ujiie A. Inhibition of PDGF- and TGF-beta-1-induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells from spontaneously hypertensive rats. Atherosclerosis 1995; 118: 213-221
22. Oshima T, Kurosawa D, Kato K, Kurosawa H, Mashima Y, Tajima S. Tranilast inhibits cell proliferation and collagen synthesis by rabbit corneal and Tenon's capsule fibroblasts. Curr Eye Res 2000; 20: 283-286
23. Ikeda H, Inao M, Fujiwara K. Inhibitory effects of tranilast on activation and transforming growth factor beta 1 expression in cultured rat stellate cells. Biochem Biophys Res Commun 1996; 227: 322-327
24. Mifsud S, Kelly DJ, Qi W et al. Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy. Nephron Physiol 2003; 95: 83-91
25. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331: 1286-1292
26. Yamamoto T, Noble NA, Miller DE, Border WA. Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Kidney Int 1994; 45: 916-927
27. Gilbert RE, Cooper ME, McNally PG, O'Brien RC, Taft J, Jerums G. Microalbuminuria: Prognostic and therapeutic implications in diabetes mellitus. Diabet Med 1994; 11: 636-645
28. Gross JL, de Azebedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: Diagnosis, prevention, and treatment. Diabetes Care 2005; 28: 164-176
29. Yagame M, Suzuki D, Jinde K et al. Significance of urinary type IV collagen in patients with diabetic nephropathy using a highly sensitive one-step sandwich enzyme immunoassay. J Clin Lab Anal 1997; 11: 110-116
30. Okonogi H, Nishimura M, Utsunomiya Y et al. Urinary type IV collagen excretion reflects renal morphological alterations and type IV collagen expression in patients with type 2 diabetes mellitus. Clin Nephrol 2001; 55: 357-364
31. Akahori H, Ota T, Torita M, Ando H, Kaneko S, Takamura T. Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression. J Pharmacol Exp Ther 2005; 314: 514-521
32. Kelly DJ, Zhang Y, Gow R, Gilbert RE. Tranilast attenuates structural and functional aspects of renal injury in the remnant kidney model. J Am Soc Nephrol 2004; 15: 2619-2629
33. Miyajima A, Asano T, Yoshimura J, Seta K, Hayakawa M. Tranilast ameliorates renal tubular damage in unilateral ureteral obstruction. J Urol 2001; 165: 1714-1718
34. Spiecker M, Lorenz I, Marx N, Darius H. Tranilast inhibits cytokine-induced nuclear factor kappaB activation in vascular endothelial cells. Mol Pharmacol 2002; 62: 856-863
35. Chikaraishi A, Hirahashi J, Takase O et al. Tranilast inhibits interleukin-1β-induced monocyte chemoattractant protein-1 expression in rat mesangial cells. Eur J Pharmacol 2001; 427: 151-158
36. Furuta T, Saito T, Ootaka T et al. The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis 1993;21:480-485
37. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 2006; 69: 73-80
38. Nakagawa H, Sasahara M, Haneda M, Koya D, Hazama F, Kikkawa R. Immunohistochemical characterization of glomerular PDGF B-chain and PDGF beta-receptor expression in diabetic rats. Diabetes Res Clin Pract 2000; 48: 87-98
39. Kelly DJ, Gilbert RE, Cox AJ, Soulis T, Jerums G, Cooper ME. Aminoguanidine ameliorates overexpression of prosclerotic growth factor and collagen deposition in experimental diabetic nephropathy. J Am Soc Nephrol 2001; 12: 2098-2107
40. Hasegawa G, Nakao K, Sawada M et al. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 1991; 40: 1007-1012
41. Gu L, Hagiwara S, Fan Q et al. Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol Dial Transplant 2006; 21: 299-313
42. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462
43. Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy: The GISEN Group. Lancet 1997; 349: 1857-1863
44. Brenner BM, Cooper ME, de Zeeuw D et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869